Agreement Allows Pediatric HIV Drug to Be Sold at Low Cost to Countries in Need

An agreement announced this morning between a UN-backed health organization and a partnership of three pharmaceutical companies will open the license for a pediatric HIV drug to be manufactured and sold at low cost to countries in need. The joint venture between Medicines Patent Pool and ViiV Healthcare — comprised of AIDS research units from GlaxoSmithKline, Pfizer and Shionogi — will let companies produce and sell the HIV drug abacavir in 118 countries.
The Jersey Journal